Investigational drug · Phase 3
REGN7508
Also called: Cenvacibart
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
10 still active
All registered trials
16
Any phase or sponsor naming "REGN7508"
First trial start
2024
Jun 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN7508", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation (AF)
- Venous Thromboembolism (VTE)
- Venous Thromboembolism
- Secondary Stroke
- Peripheral Artery Disease (PAD)
- Symptomatic Venous Thromboembolism (VTE)
- Cancer-Associated Thrombosis (CAT)
Approved drugs for the same conditions: Atrial fibrillation · Stroke prevention · Oncology · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN7508" as an intervention, largest first.
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
- Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseasePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07318610 · 7,050 participants (planned) · Start Jul 10, 2026 · Primary completion Aug 18, 2029
Drug: REGN7508; REGN9933 and 2 more · For: Peripheral Artery Disease (PAD)
Sites: Alexander City, Alabama; Avondale, Arizona; Little Rock, Arkansas · 34 sites in all
- A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult ParticipantsPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07876492 · 6,106 participants (planned) · Start Nov 20, 2026 · Primary completion Dec 15, 2029
Drug: Cenvacibart; Placebo · For: Secondary Stroke
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07430956 · 2,628 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 28, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Glendale, Arizona; Little Rock, Arkansas · 45 sites in all
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07213778 · 2,000 participants (planned) · Start Nov 24, 2025 · Primary completion May 17, 2027
Drug: REGN7508; Acetylsalicylic Acid (ASA) and 1 more · For: Symptomatic Venous Thromboembolism (VTE)
Sites: La Mesa, California; Rancho Mirage, California; Riverside, California · 57 sites in all
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07015905 · 2,000 participants (planned) · Start Jun 25, 2025 · Primary completion Feb 20, 2027
Drug: REGN7508; Apixaban and 2 more · For: Venous Thromboembolism (VTE)
Sites: Sheffield, Alabama; Riverside, California; Englewood, Colorado · 47 sites in all
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07697599 · 1,908 participants (planned) · Start Sep 7, 2026 · Primary completion Jun 25, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Venous Thromboembolism (VTE)
Sites: Tbilisi, Georgia
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07493304 · 1,600 participants (planned) · Start Aug 26, 2026 · Primary completion Jul 18, 2031
Drug: REGN7508; Apixaban · For: Venous Thromboembolism (VTE)
Sites: Hialeah, Florida; New York, New York; El Paso, Texas · 14 sites in all
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07175428 · 1,200 participants (planned) · Start Oct 20, 2025 · Primary completion Feb 9, 2027
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Fairhope, Alabama; Covina, California · 91 sites in all
- REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07410117 · 1,120 participants (planned) · Start Mar 9, 2026 · Primary completion Jan 23, 2030
Drug: REGN7508; Placebo · For: Cancer-Associated Thrombosis (CAT)
Sites: Hialeah, Florida; North Miami Beach, Florida; Boston, Massachusetts · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial.
Zwicker JI, Kithcart AP, Kaplan J, et al. · Lancet Haematol 2026
- Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).
Chalothorn D, Kithcart AP, Marin E, et al. · Blood 2026
- Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
Weitz JI, Kithcart AP, O'Brien MP, et al. · Lancet 2025
Also in development for Atrial Fibrillation (AF)
- REGN9933amrecibartPhase 35 trials
Regeneron · Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE)
- AbelacimabMAA868Phase 33 trials
Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke
- AP31969Phase 21 trial
Acesion Pharma · Atrial Fibrillation (AF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.